Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1617 1632 1653 1654 1656
This examiner grants 73% of resolved cases
David Paul Bowles is an examiner in Tech Center 1600 and Art Unit 1617. The examiner has 44 resolved cases on record. The data shows an allowance rate of 72.7% for these applications. This 72.7% allowance rate provides a metric for the frequency of successful outcomes. The median days to allowance is 1284, which establishes a timeframe for the duration of the examination process from filing to the final grant.
The profile also includes an interview lift of 22.4%. This lift indicates that conducting an interview with the examiner correlates with a change in the likelihood of success. For practitioners, the 22.4% lift suggests that direct communication is a useful strategy for addressing rejections. With 44 resolved cases, the examiner's history provides a basis for these observations. The 1284-day median to allowance remains a key consideration for managing client expectations and prosecution resources in Art Unit 1617.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18708508 | Wild Boar Cathelicidin Peptide Variants and Vectors Encoding the Same for Uses in Managing Coronavirus Infections | Non-Final OA | Georgia Tech Research Corporation |
| 18287588 | NANOPARTICLES FOR ANTIGEN-SPECIFIC CELL PROGRAMMING AND USES THEREOF | Non-Final OA | Georgia Tech Research Corporation |
| 19328859 | ANTIMICROBIAL HYDROLYZED COLLAGEN WITH POLYLYSINE AND METHODS OF USING THE SAME | Non-Final OA | Rochal Technologies, LLC |
| 17759767 | NANOMATERIALS FOR TARGETED TREATMENT OF PULMONARY TISSUE | Non-Final OA | The University of North Carolina at Chapel Hill |
| 18024871 | METHODS OF USING POLYMERIZED HUMAN SERUM ALBUMIN | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18288910 | RECOMBINANT AAVS FOR DELIVERY TO CENTRAL NERVOUS SYSTEM AND BRAIN VASCULATURE | Non-Final OA | California Institute of Technology |
| 18251133 | ANTIGEN BINDING DOMAIN WITH REDUCED CLIPPING RATE | Non-Final OA | AMGEN RESEARCH (MUNICH) GMBH |
| 17997252 | LONG-ACTING GLP-1 AND GLUCAGON RECEPTOR DUAL AGONIST | Non-Final OA | DONG-A ST CO., LTD. |
| 17923394 | ABERRANT POST-TRANSLATIONAL MODIFICATIONS (PTMS) IN METHYL- AND PROPIONIC ACIDEMIA AND A MUTANT SIRTUIN (SIRT) TO METABOLIZE PTMS | Non-Final OA | The U.S.A., as represented by the Secretary, Department of Health and Human Services |
| 18256628 | MACROPHAGE ACTIVATOR | Final Rejection | SAISEI PHARMA CO., LTD. |
| 18040398 | TOPICAL AND PARENTERAL USE AND ADMINISTRATION OF SELF-ASSEMBLING AMPHIPHILIC PEPTIDE HYDROGELS | Final Rejection | GEL4MED, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy